A5060870414- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Protease and Inhibitor Mechanisms
- Cardiac Structural Anomalies and Repair
- Prostate Cancer Diagnosis and Treatment
- Oxidative Organic Chemistry Reactions
- Neuropeptides and Animal Physiology
- Catalytic C–H Functionalization Methods
- Medical Imaging and Pathology Studies
- Mass Spectrometry Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Fluorine in Organic Chemistry
- Signaling Pathways in Disease
- Synthesis and Catalytic Reactions
- Click Chemistry and Applications
- S100 Proteins and Annexins
- Chemical Synthesis and Analysis
- Functional Brain Connectivity Studies
- Neurotransmitter Receptor Influence on Behavior
- Porphyrin and Phthalocyanine Chemistry
- Pancreatic and Hepatic Oncology Research
- Cardiac tumors and thrombi
- Vanadium and Halogenation Chemistry
Hochschule Düsseldorf University of Applied Sciences
2025
Heinrich Heine University Düsseldorf
2021-2024
Düsseldorf University Hospital
2021-2024
Klinik und Poliklinik für Nuklearmedizin
2023-2024
Heidelberg University
2014-2023
University Hospital Heidelberg
2020-2023
Ludwig Boltzmann Institute Applied Diagnostics
2017-2022
Medical University of Vienna
2018-2022
German Cancer Research Center
2014-2020
DKFZ-ZMBH Alliance
2016
The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, this motivated consideration 18F-labelled analogs. 18F-PSMA-1007 was selected among 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake fast, non-urinary background...
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them had a high clinical impact on treatment patients with prostate cancer. However, number <sup>18</sup>F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop radiofluorinated molecule resembling structure therapeutic PSMA-617. <b>Methods:</b> The nonradioactive reference compound PSMA-1007 and precursor were produced by solid-phase...
Abstract Purpose FAPI ligands (fibroblast activation protein inhibitor), a novel class of radiotracers for PET/CT imaging, demonstrated in previous studies rapid and high tumor uptake. The purpose this study is the head-to-head intra-individual comparison 68 Ga-FAPI versus standard-of-care 18 F-FDG organ biodistribution uptake patients with various cancers. Material Methods This international retrospective multicenter analysis included data from 71 6 centers who underwent both within median...
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for PET-imaging of prostate cancer. In this connection, we recently developed fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures automated radiosyntheses developed. We herein report on both...
68Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT represents an advanced method for the staging of primary prostate cancer (PCa) and diagnosis recurrent or metastatic PCa. However, because narrow availability 68Ga development alternative tracers is high interest. The objective this study was to examine value new PET tracer 18F-PSMA-1007 local disease by comparing it with multiparametric MRI (mpMRI) radical prostatectomy (RP) histopathology. Methods: In 2016, performed in 10 men...
The biochemical and radiological responses to radionuclide therapy with Lu-PSMA-617 targeting prostate-specific membrane antigen (PSMA) make it a promising approach the treatment of patients metastatic castration-resistant prostate cancer (mCRPC) [1]. However, PSMA-617 has been reported have slower tumour accumulation clearance kinetics than PSMA-11, latter is still therefore preferred diagnostic agent when labelled generator-produced Ga which short half-life (68 min) [2]. A PSMAtargeting...
Abstract Background Cancer-associated fibroblasts are found in the stroma of epithelial tumors. They characterized by overexpression fibroblast activation protein (FAP), a serine protease which was already proven as attractive target for chelator-based theranostics. Unfortunately, value gallium-68 labeled tracers is limited their batch size and short nuclide half-life. To overcome this drawback, radiolabeling with aluminum fluoride complexes 6-fluoronicotinamide derivatives longer-lived...
The <sup>18</sup>F-labeled fibroblast activation protein inhibitor (FAPI) [<sup>18</sup>F]FAPI-74 has the benefit of a higher synthetic yield and better image resolution than <sup>68</sup>Ga-labeled FAPI. We preliminarily evaluated diagnostic performance PET in patients with various histopathologically confirmed cancers or suspected malignancies. <b>Methods:</b> enrolled 31 (17 men 14 women) lung cancer (<i>n</i> = 7), breast 5), gastric pancreatic 3), other benign tumors 6). Twenty-seven...
Iodonium ylide precursors of electron rich arenes, <italic>i.e.</italic> the NET and SERT ligands 4-((3- 4-fluorophenoxy)phenylmethyl)piperidine, served as model compounds for direct substitution with n.c.a. [<sup>18</sup>F]fluoride.
Ga-FAPI (fibroblast activation protein inhibitor) is a rapidly evolving and highly promising radiotracer for PET/CT imaging, presenting excellent results in variety of tumor entities, particularly epithelial carcinomas. This retrospective analysis sought to evaluate the potential impact FAPI-PET/CT rare cancer diseases with respect improvement staging therapy, based on tracer uptake normal organs tumors.
Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment metastatic castration-resistant prostate cancer (CRPC). Astatine an α-emitter (half-life=7.2 h) that can be produced by 30-MeV cyclotron. This study evaluated the effect of 211At-labeled PSMA compounds in mouse xenograft models.Tumor models were established subcutaneous transplantation human cells (LNCaP) NOD/SCID mouse. [211At]PSMA1, [211At]PSMA5, or [211At]PSMA6 was administered to LNCaP mice...
Abstract The discovery of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET) has paved the way for a new class PET tracers that target tumor microenvironment (TME) rather than itself. Although 18 F-fluorodeoxyglucose (FDG) is most common tracer used in clinical imaging cancer, multiple studies have now shown family FAP ligands commonly outperform FDG detecting cancers, especially those known to lower uptake on FDG-PET. Moreover, FAPI-PET will applications benign...
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. <sup>68</sup>Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved imaging. However, several <sup>18</sup>F-labeled that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of <sup>18</sup>F-PSMA-1007 in with BCR. <b>Methods:</b> Twelve BCR treatment underwent PET/CT scans 1 and 3 h injection...
Clinical Practice Points•To date, several radioactive tracers for imaging primary and recurrent prostate cancer are undergoing active investigation.•In this case report fluorine-18 (18F)–prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/computed was performed, to our knowledge, the first time in a patient with biochemical recurrence (prostate-specific [PSA] 0.08 μg/L) after radical prostatectomy adjuvant radiation.•Seventeen lymph nodes increased tracer uptake...
Fibroblast activation proteins (FAP) are overexpressed in the tumor stroma and have received attention as target molecules for radionuclide therapy. The FAP inhibitor (FAPI) is used a probe to deliver nuclides cancer tissues. In this study, we designed synthesized four novel 211At-FAPI(s) possessing polyethylene glycol (PEG) linkers between FAP-targeting 211At-attaching moieties. piperazine (PIP) linker FAPI exhibited distinct selectivity uptake FAPII-overexpressing HEK293 cells lung cell...
18F-labeled prostate-specific membrane antigen (PSMA) ligand, [18F]PSMA-1007, has the benefit of a higher synthetic yield and minimal excretion in urine. High detection efficacy was reported biochemical recurrence (BCR) prostate cancer after radical prostatectomy. Thus, we evaluated preliminary diagnostic utility [18F]PSMA-1007 PET patients with cancer, focusing on BCR which is not detected conventional imaging.We enrolled total 28 (age 51-79 years) cancer. defined as continuous increase PSA...
Currently, targeted alpha therapy (TAT) is a new involving the administration of therapeutic drug that combines substance α-emitting nuclides kill cancer cells and selectively accumulates in cells. It known to be effective against cancers are difficult treat with existing methods, such as widely spread throughout whole body, there high expectations for its early clinical implementation. The TAT, including
Abstract The human trophoblast cell-surface antigen 2 (Trop-2) is expressed in a variety of malignant diseases. Using pretargeting methodology, novel antibody against Trop-2 was radiolabeled and evaluated preclinical setting. This showed promising characteristics lending itself as potential basis for further clinical trials imaging agent theranostic.